Doximity (DOCS)
(Real Time Quote from BATS)
$56.28 USD
-6.30 (-10.07%)
Updated Nov 7, 2025 10:42 AM ET
3-Hold of 5 3
NA Value NA Growth NA Momentum NA VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DOCS 56.28 -6.30(-10.07%)
Will DOCS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for DOCS based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for DOCS
Doximity (DOCS) Reports Next Week: Wall Street Expects Earnings Growth
OMCL vs. DOCS: Which Stock Is the Better Value Option?
DOCS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Doximity (DOCS) Declines More Than Market: Some Information for Investors
Doximity (DOCS) Upgraded to Strong Buy: Here's Why
Doximity (DOCS) Stock Slides as Market Rises: Facts to Know Before You Trade
Other News for DOCS
Analysts Offer Insights on Healthcare Companies: Doximity (DOCS), Cartesian Therapeutics (RNAC) and Anixa Biosciences (ANIX)
Doximity (DOCS): Analyst Rating and Price Target Updates for November 7, 2025 | DOCS Stock News
Doximity price target lowered to $70 from $81 at Evercore ISI
Doximity price target lowered by $11 at Evercore ISI, here's why
DOCS Fell Below 200 Day Moving Average on November 6